Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

Mise à jour : Il y a 4 ans
Référence : NCT00833664

Femme et Homme

Extrait

The Purpose of this study os to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and female adult subjects.


Critère d'inclusion

  • Healthy

Liens